RxDoctor Payments Data

Felix Lopez Bermudez, MD

General Practice · Altamonte Springs, FLNPI 1356683767

Payments from drug & device makers

$2,610in general payments, 2019–2025

Across 36 payments — averaging $72.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Photonicare Inc$2K
  • AbbVie$308
  • GSK$182
  • Novo Nordisk$119
  • Pfizer$45
  • AstraZeneca$40
  • plus $95 from 4 others

What the payments were for

  • Food & beverage$86033%
  • Other$1,75067%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Photonicare Inc4$1,822
AbbVie(2 entities)7$308
GSK6$182
Novo Nordisk8$119
Pfizer2$45
AstraZeneca3$40
Merck2$39
Novartis2$29
Sanofi1$15
Lilly USA, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,610 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$48,232
Medicare patients
69
Services billed
1,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$81,929
TrulicityDulaglutide38$42,856
EliquisApixaban43$36,656
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$34,675
JardianceEmpagliflozin24$29,408
MounjaroTirzepatide14$15,973
SymbicortBudesonide/Formoterol Fumarate44$13,794
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$13,363
TradjentaLinagliptin12$12,695
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$11,627
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp21$6,824
Albuterol Sulfate HfaAlbuterol Sulfate143$6,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,975
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$4,348
Atorvastatin Calcium292$3,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$81,92963 claims
Lilly USA, LLCTrulicity, Mounjaro$12$58,82952 claims
PfizerEliquis$45$36,65643 claims
GSKTrelegy Ellipta$182$34,67543 claims
AstraZenecaSymbicort$40$13,79444 claims
AbbVieCreon$308$93011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →